Category: ACN Newswire

香港, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀今日宣布，中國台灣地區藥政主管部門（TFDA）已正式受理維長寧（艾曲莫德，中國台灣地區商品名：「維長寧」）用於治療中重度活動性潰瘍性結腸炎（UC）患者的新藥上市許可申請（NDA）。這一進展標志著艾曲莫德繼在中國澳門、新加坡和中國香港獲批以及韓國NDA獲正式受理之後，在亞洲市場的准入取得又一重大里程碑。中國國家藥品監督管理局也於2024年12月正式受理艾曲莫德（維適平(R)）的新藥上市申請，預計將在今年年底或明年年初獲批。艾曲莫德是一款針對潰瘍性結腸炎，每日一次的口服一線治療藥物，能夠強效實現腸道黏膜愈合，且使用便捷，並具有良好的安全性特征。黏膜愈合是國內外潰瘍性結腸炎臨床指南一致認定的潰瘍性結腸炎治療目標。潰瘍性結腸炎患者盡早實現黏膜愈合，可大幅降低疾病複發率、住院率、結直腸切除手術率和結直腸癌發生風險。艾曲莫德已被納入2024年美國胃腸病學協會（AGA）臨床實踐指南, 推薦作為潰瘍性結腸炎的一線治療。2025年，艾曲莫德獲得2025年美國胃腸病學會（ACG）成人UC臨床指南的一線治療推薦，進一步印證了其全球專業共識下的臨床價值。雲頂新耀首席執行官羅永慶先生表示：「此次在中國台灣地區NDA申請的正式受理，是維長寧亞洲商業化進程中的又一重要進展。隨著亞洲地區潰瘍性結腸炎患者人數持續增長，臨床上存在巨大未滿足需求。僅在中國，2024年潰瘍性結腸炎患者數量約為80萬人，預計到2030年將達100萬人。患者面臨長期治療與生活質量的雙重挑戰。此次受理充分體現了對維長寧臨床價值的高度認可。我們將繼續加快這一創新療法在中國大陸及亞洲其他市場的上市進程，提升可及性，幫助患者實現長期疾病控制並改善生活質量。」本次申請基於ELEVATE UC III期注冊研究（ELEVATE UC 52和ELEVATE UC 12）和ENLIGHT研究（ES101002）的結果。ELEVATE UC III期注冊研究顯示，在既往常規治療、生物制劑或JAK抑制劑治療失敗或不耐受的中重度活動性潰瘍性結腸炎患者中，每日一次2mg艾曲莫德在第12周和第52周均顯示卓越且持久的臨床緩解和內鏡下深度黏膜愈合，且安全性良好，與既往研究一致。同時，ENLIGHT研究作為迄今最大規模的亞洲中重度UC III期注冊臨床研究，在中國大陸、中國台灣及韓國開展，共納入340名患者。研究結果顯示，艾曲莫德在誘導期和維持期均取得了顯著且具有統計學意義的療效優勢，為其在亞洲人群中的應用提供了有力證據支持。作為雲頂新耀在自身免疫性疾病領域的重磅產品，艾曲莫德已於2024年被納入粵港澳大灣區內地9市臨床急需進口港澳藥品醫療器械目錄，在大灣區先行使用，惠及UC患者，並成為公司第三款商業化新藥。今年3月，雲頂新耀已啟動艾曲莫德在嘉善工廠的本地化生產建設項目，以支持其在大中華區及亞洲其他市場的供應與商業化落地。 Copyright 2025 亞太商訊 via SeaPRwire.com.

阿聯酋拉斯海瑪市, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - 阿勒哈伊馬國際公司註冊中心（RAK ICC）宣布對其2019年《基金會條例》進行重大修訂，新規已於2025年7月31日生效。此次修訂是該制度自推出以來最為重要的更新之一，進一步鞏固了阿聯酋作為財富架構與長期資產保護競爭性司法管轄區的地位。RAK ICC基金會因其靈活性、保密性及法律穩健性而廣受認可，成為阿聯酋國內外高淨值人士、企業家及家族辦公室的首選架構工具。這類結構通常用於繼承規劃、家族治理，以及將多元化資產整合於單一法律實體之下。2025年的修訂引入了更強的法律保障及改進的治理措施，包括：1. 防火牆條款 —— 對與RAK ICC法規相衝突的外國判決提供更強有力的保護。2. 三年訴訟時效 —— 將對基金會設立或資產轉移提出異議的時限限制為三年。3. 訴因條款 —— 債權人欺詐索賠僅限於涉案的特定資產，且僅在該行為導致創辦人資不抵債時才適用。4. 脅迫與高管保護 —— 宣告在外國法律脅迫下採取的行為無效，從而保障基金會內部治理的自主權。5. 強化仲裁機制 —— 允許通過具備法院級權力的私下仲裁方式解決爭議。6. 私人受託基金會條款 —— 明確基金會作為受託人持有財產時的資產隔離及受信義務的完整性。RAK ICC基金會持有的資產現將享有更強的防火牆保護，確保與阿聯酋法律相衝突的外國判決無法對其執行。新規設立了三年的時效期，用於限制對基金會成立或資產轉入的質疑，為創辦人及受益人提供更大的確定性。改革還收緊了債權人保護規則，在欺詐性轉讓索賠中須證明創辦人資不抵債，並將責任限定在爭議資產的價值範圍內，以防涉及無關財產。此外，修訂後的法規著重維護治理完整性和營運韌性。基金會高管在收到與RAK ICC法律不一致的外國命令時，必須予以忽略，從而保障基金會決策的自主權。新框架明確規定，基金會作為受託人持有的信託財產在法律上獨立且與基金會自有財產分離，確保資產隔離的清晰性。爭議解決機制也得到了強化，擴大的仲裁條款賦予仲裁庭類似法院的權力，使爭議能夠高效、保密地解決，並符合國際最佳實踐。這些變化是RAK ICC維護前瞻性法律與監管環境整體戰略的一部分，旨在滿足全球標準的同時兼顧客群的特定需求。這也體現了該司法管轄區在支持兼顧控制、隱私與長期安全的高端財富規劃策略方面的承諾。透過強化其基金會制度，RAK ICC正鞏固其在阿聯酋的地位，成為尋求安全、靈活且符合國際合規標準的財富保全與跨代規劃解決方案的可信賴合作夥伴。關於RAK ICC阿勒哈伊馬國際公司註冊中心（Ras Al Khaimah International Corporate Centre，簡稱RAK ICC）是一家總部位於阿聯酋阿勒哈伊馬的公司註冊機構。該機構提供國際商業公司及基金會架構，通常用於私人及商業結構設計、資產整合以及繼承規劃。截至目前，RAK ICC已註冊成立數千家國際公司，並為數十億迪拉姆的結構化資產提供支持。其服務對象包括高淨值人士、企業家及尋求靈活、安全的長期商業與財富管理方案的企業。媒體諮詢請聯絡我們:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/來源: RAK ICC Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - 中國辣味休閒食品行業龍頭企業，卫龙美味全球控股有限公司（「卫龙美味」或「集團」）及附屬公司（「集團」）（香港聯交所股票代碼：09985.HK）公佈截至2025年6月30日止六個月（「期內」）之中期業績。人民幣截至6月30日止六個月2025年2024年變動收入34.83億29.39億+18.5%毛利16.42億14.62億+12.3%毛利率47.2%49.8%-2.6個百分點期內淨利潤7.36億6.21億+18.5%淨利潤率21.1%21.1%保持穩定中期股息0.18元/普通股0.16元/普通股+12.5%2025年上半年，在全球消費增長普遍承壓下，中國消費市場依然是全球最大消費市場之一。得益於中國休閒食品市場近年來呈現出穩健的增長態勢，報告期內，卫龙美味緊跟行業發展趨勢，堅持多品類產品策略，聚焦創新，深度開展消費者洞察，精準捕捉市場需求，持續強化研發實力，並持續以年輕人喜愛的方式深化品牌滲透，通過各種線上線下的品牌活動搭建多維消費場景鏈接深化品牌滲透，持續推進全渠道覆蓋能力和銷售網絡，進而為客戶及消費者提供更好的服務和體驗。報告期內，卫龙美味經營策略成效彰顯，業績持續穩健攀升，收入與淨利潤均錄得雙位數增長。2025年上半年實現總收入34.83億元（人民幣，下同），同比增長18.5%，主要由於集團期內持續加強全渠道和品牌建設，並優化渠道結構。儘管報告期內部分原材料成本上漲導致集團毛利率由去年同期的49.8%下降2.6個百分點至47.2%，但在收入增長及集團積極提升供應鏈效率的共同因素驅動下，毛利仍同比增長12.3%至16.42億元。同時受惠於集團經營利潤的提升，集團期內凈利潤同比增長18.5%，至7.36億元；淨利潤率得以維持去年同期相同水平，為21.1%。基於期內整體績效表現，集團董事會決議派發2025年中期股息每股人民幣0.18元，派息比率約為60%，預計派付股息日期為2025年10月20日或前後。產品方面，集團堅持多品類產品策略，從新產品、新口味、新工藝、新包裝等維度發力，如拓展風味創新邊界，深度回應消費者對創新口味的需求。2025上半年，集團先後推出了麻醬口味「魔芋爽」和麻辣牛肉口味「親嘴燒」等多個新品，進一步拓展並豐富產品組合，提升產品品質，滿足市場多元化及個性化的消費需求，驅動產品力與市場需求匹配。品牌建設方面，集團持續以年輕人喜愛的方式深化品牌滲透，透過各種線上線下的品牌活動搭建多維消費場景鏈接，譬如聯合林里檸檬茶發起「爆辣挑戰」，憑藉爆款銷量與話題效應觸達更多消費者；攜手國潮品牌哭喊中心推出「大兒童專屬」系列，借節日營銷勾起青春味覺記憶。此外，集團於報告期內官宣王安宇擔任魔芋爽代言人，借力明星影響力拓寬傳播路徑。集團的一系列舉措有效觸達年輕客群，夯實了品牌年輕化與趣味化的發展根基。渠道方面，集團持續推進線下全渠道、線上全平台覆蓋策略。隨著各種新興渠道業態的興起，集團緊跟渠道變化，持續拓展終端網點，強化銷售團隊終端執行力，並聯合經銷商持續提升終端的服務能力和產品鋪市率，從而有力推動線下終端業績穩步增長。在線上領域，集團同樣積極佈局，構建全平台生態體系，確保與線下渠道形成有效聯動，助力全渠道發展戰略落地。此外，集團始終致力於生產設施的自動化升級與技術創新突破，同步加快各業務系統的數字化轉型進程。在此基礎上，集團不斷強化組織發展與核心人才梯隊建設，以此全面提升公司整體運營效能，為業務的持續穩健發展注入強勁動力。卫龙美味董事長劉衛平先生表示：「集團將始終堅守『多品類』產品策略，堅持產品創新，持續加碼品牌建設力度，不斷強化卫龙『年輕、有趣、有創意』的品牌形象與獨特調性。與此同時，集團積極擁抱變化，持續加強全渠道的覆蓋能力，為消費者提供更便捷的消費體驗。展望未來，集團將以更積極、更主動的心態擁抱市場的變化，以更好的產品、更優質的服務和體驗不斷提升我們的競爭力，持續為消費者、客戶、員工、投資人及社會創造更大的價值。」關於卫龙美味全球控股有限公司卫龙美味全球控股有限公司（「卫龙美味」）是中國領先的集研發、生產及銷售為一體的辣味休閒食品企業，擁有強勁的增長勢頭和頗具影響力的品牌。 卫龙美味以傳統美食為基礎開創了中國調味麵製品（俗稱「辣條」）行業，於2001年開創出第一根辣條，並引領了辣條行業標準建設。 憑藉出眾的品類拓展能力，本集團已成功擴展至蔬菜製品、豆製品及其它產品等品類，推出了包括魔芋爽、風吃海帶、小魔女等大單品。 卫龙美味是倍受中國年輕消費者喜愛的休閒食品品牌，擁有有效觸達年輕消費者的全渠道銷售及經銷網路。 如欲獲得更多資訊，請流覽： https：//www.weilongshipin.com/。 Copyright 2025 亞太商訊 via SeaPRwire.com.

東京, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd.（總公司：東京都中央區，執行總裁：田中 浩一朗）決定與株式會社JEPLAN（總公司：神奈川縣川崎市，代表取締役 社長兼執行總裁：高尾 正樹，以下稱「JEPLAN」）進行事業合作，旨在削減以產業用貴金屬展開事業的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.於貴金屬回收製程的CO2排放，以及實現有機物的再資源化。此項舉措是由在貴金屬領域上持續努力實現循環經濟（Circular Economy）的TANAKA以及在塑膠領域上持續努力的JEPLAN協力合作，以實現脫碳和循環型社會為目標。TANAKA為實現循環型社會迄今所採取的舉措TANAKA自1885年創業以來，作為貴金屬業界的龍頭企業，長年致力於稀缺資源的貴金屬回收。特別是在接受客戶委託回收的製程廢棄物當中，本公司針對以有機物（塑膠）為主要成分且有貴金屬附著或吸附的製程廢棄物，迄今持續採用焚燒處理來去除有機物，並從剩餘的灰燼中回收貴金屬。在此焚燒處理中，雖然已針對去除環境管制物質進行應對，但要削減於燃燒有機物的過程中所產生的CO2，仍然是邁向實現脫碳社會的課題。透過與JEPLAN的事業合作而改變的貴金屬回收製程JEPLAN以一種稱作聚乙烯對苯二甲酸酯的塑膠為目標對象來建立獨家的化學回收技術。為了解決上述的CO2排放量課題，TANAKA藉由與JEPLAN的事業合作，正在研討除了過去採用焚燒處理的貴金屬回收製程以外，未來還可能利用化學回收處理。化學回收處理的目標對象估計是注射器、合成纖維擦拭布等塑膠。而在作為目標對象的貴金屬回收製程中CO2排放量預計可比過去抑制10%左右。另外，本製程不僅是回收貴金屬還可使塑膠再生，使TANAKA和JEPLAN在各自的專門領域中，為實現脫碳和循環型社會作出貢獻。株式會社JEPLAN總公司所在地：神奈川縣川崎市川崎區扇町12-2設立：2007年1月代表人：代表取締役 社長兼執行總裁 高尾 正樹主要事業內容：PET化學回收技術相關事業（目標對象：PET瓶、聚酯纖維）等官方網站：http://www.jeplan.co.jpJEPLAN提出以「讓所有物品進行循環使用」為使命，並以實現循環經濟為目標。以廢PET（PET瓶、聚酯纖維等）為目標對象，藉由使用獨家的PET化學回收技術分解至分子等級並去除雜質，使其重生轉變為具有與源自石油相同品質的再生素材。藉由使用使此獨家技術致力於回收，以實現循環使用有限的資源，也有助於削減CO2的排放量。關於TANAKATANAKA自1885年（明治18年）創業以來，營業範圍向來以貴金屬為中心，並以此展開廣泛活動。在日本國內，以最高水準的貴金屬交易量為傲的TANAKA，長年以來除了進行產業用貴金屬產品的製造和販售外，也供應貴金屬製作珠寶飾品和投資型貴金屬商品。本集團以貴金屬專業團隊之姿，旗下的國內外各集團公司協調合作，使製造、販售與技術一體化，並供應相關產品與服務。2024 年度（2024年12月止）的合併營業額為8,469億日圓，擁有5,591名員工。產業事業全球網站https://tanaka-preciousmetals.com產品諮詢表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-on-industrial-products/新聞媒體諮詢處TANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-for-media/新聞稿: https://www.acnnewswire.com/docs/files/20250814_CT.pdf Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年8月14日 - (亞太商訊 via SeaPRwire.com) - 富衛集團有限公司（「富衛集團」或「富衛」）今天宣布了12項社區關愛撥款計劃，支援亞洲各地的本地社區，慶祝成立 12週年。自2013年成立以來，富衛集團從香港特別行政區、澳門特別行政區和泰國起步，現已擴展至亞洲共十個市場，包括柬埔寨、印尼、日本、馬來西亞、菲律賓、新加坡和越南。12項社區關愛撥款計劃將聚焦支持非政府機構，推動涵蓋理財素養、社會創業、就業準備及身心健康福祉等範疇的倡議。富衛集團行政總裁兼執行董事黃清風表示：「今年以新上市公司的身份慶祝富衛成立12週年，令這個里程碑更具意義。人壽保險業務極具個人化，而富衛現已服務亞洲三千萬客戶及其家庭。我們以『細心關懷』為核心價值之一，透過實質且有影響力的方式回饋社會，是實現我們為大眾創造保險新體驗此願景的重要實踐。」富衛集團於今年早前宣佈與JA（Junior Achievement）Worldwide延長合作夥伴關係。JA Worldwide是一家專注於青少年發展的慈善機構，也是 2025 年諾貝爾和平獎的提名機構。富衛與JA共同開發且屢獲殊榮的理財素養課程，預期到2027年底將惠及亞洲40,000多名學生。計劃的下一階段將透過推出全新教學工具，並與更多教師和家長攜手合作，加強於理財素養，心理健康和韌性的教育和知識。12項慈善機構撥款計劃包括：- 柬埔寨：與 Cambodia Children's Fund合作，推出「Let’s Save Debate」計劃，透過辯論與研究活動提升大學生的理財素養；- 香港：與青年成就香港部合作，進一步擴展「JA小財智．大夢想」課程，推出「JA SparktheDream同『理』．理財工作坊」，為小學生提供結合理財素養及社交情感學習的互動教育；支持睿動香港透過運動賦予青少年女性心理健康與自信；- 印尼：與 KUMPUL.ID 合作，支持「InnovateHer Academy 3.0」 計劃，為女性企業家提供商業技能培訓、導師指導及投資準備課程；與Prestasi Junior Indonesia合作，並借鑒 「JA小財智．大夢想」計劃的成功經驗，為30名學校教師提供技術培訓，讓他們能有效地為學生傳授理財素養課程；- 日本：與 NPO全國福祉理美容師養成協會（National Welfare Beauty and Barber Training Association）合作，在國際乳癌關注月向癌症患者提供醫療假髮及支援；- 馬來西亞：與GivingHub啟動「Bijak Ibu Jaga Anak & Kewangan （B.I.J.A.K. ）」計劃，為200個低收入家庭舉辦工作坊，推廣健康及理財素養，並提供200項健康篩查與諮詢服務；- 菲律賓：與Junior Achievement Philippines合作，通過「JA Forward Your Success」計劃協助應屆大學畢業生規劃財務與職業發展；- 新加坡：支持 Club Rainbow （Singapore） 的 「Ride and Walk for Rainbows 2025」 活動，為長期病患兒童及其家人提供支援，並安排罕見遺傳及神經疾病青少年參觀萬態野生動物世界 （Mandai Wildlife Reserve）；- 泰國：與Pimali Foundation合作資助七個酒店管理培訓獎學金，以協助弱勢青年建立可持續的職涯發展；與Junior Achievement Thailand合作，進一步擴展「JA小財智．大夢想」計劃，培訓30名教師，深化其理財素養技能以支援學生；- 越南：與 Startup Vietnam Foundation合作，支援「Be A Finnovator」計劃，舉辦大學生培訓及辯論比賽，培養金融知識、批判性思維與負責任的理財習慣。關於富衛集團富衛集團為泛亞洲人壽及健康保險公司，服務約三千萬名客戶，業務遍及亞洲十個市場，包括印尼人民銀行人壽保險（BRI Life）。富衛秉持以客為先的方針及科技賦能的模式，致力為客戶帶來創新定位、簡單易明的產品和簡單的保險體驗。自2013年成立以來，富衛於部分全球發展最迅速的保險市場營運業務，專注為大眾創造保險新體驗。富衛集團是香港聯合交易所有限公司主板上市的公司，股份代號為1828。如欲了解更多資訊，請瀏覽www.fwd.com Copyright 2025 亞太商訊 via SeaPRwire.com.

SINGAPORE, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - SGX Catalist-listed AsiaMedic Limited (the “Company” and, together with its subsidiaries, the “Group”) announced its unaudited financial results for the six months ended 30 June 2025 (“1H2025”), delivering 26% year-on-year revenue growth to S$16.6 million, up from S$13.2 million in 1H2024.This performance was led by the Group’s diagnostic imaging business, which contributed over 60% of total revenue, supported by strong demand at its flagship Shaw Centre clinic and contributions from the newly opened Novena imaging centre.Financial Highlights:Revenue up 26% to S$16.6 million, from S$13.2m in 1H2024, driven by strong growth in diagnostic imaging and steady performance in medical wellness.EBITDA attributable to owners of the Company was maintained at S$1.3 million, reflecting consistent contributions from core businesses, even as the new Novena centre incurred ramp-up losses.Net loss attributable to owners of the Company narrows significantly to S$38,603 from S$104,431 in 1H2024.Cash and cash equivalents stood at S$4.9 million, with an additional S$3.6 million in financial assets, reflecting strong underlying liquidity despite investments into Novena centre.Profitability was significantly affected by the new Novena imaging centre as it remains in its ramp-up phase. However, the Group’s financial performance reflects solid execution of its core business strategy amidst expansion.Mr Arifin Kwek (郭致宾), Chief Executive Officer of AsiaMedic Limited, said, “Our performance in the first half of 2025 reflects the continued strength of our diagnostic imaging business. Shaw Centre remained our primary growth engine with sustained patient volumes, while the newly opened Novena Centre, though still ramping up, has already begun contributing. These investments will further position us as a trusted provider of early detection and preventive care in Singapore.Our health screening and medical wellness segment remained stable, underpinned by the government awarded Grow Well SG programme and steady corporate wellness demand. While the opening of Novena has added to our cost, these are deliberate investments in capacity, technology, and skilled professionals in a key medical geographical location in Singapore, that position us for long term growth.We will continue to build on this foundation, focusing on scaling our imaging and health screening businesses while ensuring we deliver high quality, patient-centred care. With expanded capacity and prudent cost management, AsiaMedic is well placed to capture growth opportunities in Singapore’s healthcare sector.”As Singapore continues to position itself as a regional healthcare hub, AsiaMedic is well-placed to meet growing demand for accessible, high-quality diagnostic and preventive healthcare services. With established centres in Orchard and Novena — two of the country’s key medical precincts — the Group is strategically expanding its reach to serve a broader patient base. This geographic presence, supported by ongoing investments in technology, infrastructure, and clinical talent, positions AsiaMedic to play a meaningful role in advancing Singapore’s preventive care and early detection agenda.This media release should be read in conjunction with the financial statements announced on SGXNet.About AsiaMedic LimitedAsiaMedic Limited together with its subsidiaries (“AsiaMedic” or the “Group”) is a leading healthcare provider in Singapore which provides holistic solutions through integrated application of the latest medical technologies to preventand detect early illnesses to achieve positive experiences and clinical outcomes for patients. AsiaMedic is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (SGX-ST).The Group is committed to helping clients through practical and personalised solutions delivered with the highestprofessional standards of service and expertise in a timely, safe and consistent manner.With convenient locations at Orchard and Novena, AsiaMedic is a preferred one-stop centre for:Diagnostic imaging and radiology servicesMedical wellness and health screening servicesPrimary healthcare servicesMedical aesthetic services and productsFor more information, please visit www.asiamedic.com.sgFor media and analysts’ queries, please contact:Waterbrooks ConsultantsWayne KooT: (65) 9338 8166 / (65) 8901 9780E: wayne.koo@waterbrooks.com.sg / query@waterbrooks.com.sgThis announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examinedor approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Following the lifting of the Black Rainstorm Warning Signal at 11:10am, the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO and Hong Kong International Tea Fair will reopen at 1:10pm.The Food Expo, Beauty & Wellness Expo, Home Delights Expo will be extended and close at 11pm from 15 August to 17 August, allowing public visitors to enjoy shopping in these fairs—with a single ticket. The Food Expo PRO and Hong Kong International Tea Fair will remain open until 6pm today and tomorrow (14 to 15 August) and until 5pm on Saturday (16 August), enabling trade buyers and exhibitors to continue their business discussions.Admission tickets valid for today may be used for entry on any of the remaining fair days.Sessions 2 and 3 of the International Conference of the Modernization of Chinese Medicine afternoon programme will be resumed in a hybrid format.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - FWD Group Holdings Limited (“FWD Group” or “FWD”) today marked its 12th anniversary by announcing 12 charitable grants dedicated to supporting local communities across Asia.Since its founding in 2013, FWD has grown from its beginnings in Hong Kong SAR, Macau SAR, and Thailand to now span 10 markets across Asia, including Cambodia, Indonesia, Japan, Malaysia, the Philippines, Singapore, Vietnam.The 12 grants are focused on supporting non-government organisations (NGOs) with initiatives spanning financial literacy, social entrepreneurship, career readiness, and health and wellbeing in communities.Huynh Thanh Phong, Group Chief Executive Officer and Executive Director of FWD Group, said, “Celebrating our 12th anniversary as a newly listed company makes this milestone especially meaningful. The life insurance business is a deeply personal one, with FWD now touching the lives of 30 million people and their families across Asia. With caring as one of our core values at FWD, giving back in tangible and impactful ways to the wider community is a big part of our vision of changing the way people feel about insurance.”Earlier this year, FWD extended its regional partnership with JA (Junior Achievement) Worldwide – a youth-focused charity and Nobel Peace Prize 2025 nominee – to reach 40,000 more students across Asia by the end of 2027 with its award-winning financial literacy programme. In the next phase, the programme aims to integrate new tools to strengthen financial literacy, mental wellness, and resilience – while involving more teachers and families in the process.The 12 NGO grants include:- Cambodia: Partnering with Cambodia Children’s Fund to launch the "Let’s Save Debate," a university-level initiative promoting financial literacy through debate and research.- Hong Kong SAR: Expanding the JA SparktheDream programme with Junior Achievement Hong Kong and introducing the JA SparktheDream Wellness Workshop that blends financial education with social and emotional learning to engage primary school students.Supporting WISE (Women In Sports Empowered Hong Kong Limited) with its programme to empower teenage girls through sports for mental wellbeing and self-confidence.- Indonesia: Supporting InnovateHer Academy 3.0 with KUMPUL.ID to equip female entrepreneurs with business skills, mentorship, and investment readiness skills.Launching a new financial education programme with Prestasi Junior Indonesia on the back of the best practices from the JA SparktheDream programme. The new programme will equip 30 school teachers with the skills and knowledge to deliver engaging and effective financial literacy lessons.- Japan: Partnering with the National Welfare Beauty and Barber Training Association to provide medical wigs and support for cancer patients during Breast Cancer Awareness month.- Malaysia: Launching the Bijak Ibu Jaga Anak & Kewangan (B.I.J.A.K.) programme with GivingHub to provide 200 low-income families with health and financial literacy educational workshops as well as 200 health screenings and consultations.- Philippines: Collaborating with Junior Achievement Philippines on JA Forward Your Success to support graduating college students with financial literacy and career planning.- Singapore: Supporting Club Rainbow (Singapore) in helping children with chronic illnesses and their families by joining Ride & Ralk for Rainbows 2025, along with a visit to Mandai Wildlife Reserve for children and youths with rare genetic and neurological disorders.- Thailand: Sponsoring seven hospitality scholarships via Pimali Foundation for disadvantaged youth, helping them build sustainable careers.Expanding the JA SparktheDream programme with Junior Achievement Thailand by training 30 teachers in financial literacy to deepen their financial management skills and better support students.- Vietnam: Supporting Be A Finnovator with the Startup Vietnam Foundation on a training and debate competition for university students to build financial leadership, critical thinking, and responsible money habits.About FWD GroupFWD Group is a pan-Asian life and health insurance business that serves approximately 30 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code 1828. For more information, please visit www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - As the Black Rainstorm Warning Signal was issued at 7:50am, the opening of Food Expo, and the concurrent Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo, will be postponed. The opening ceremony originally scheduled for 10:30am, is cancelled. The International Conference of the Modernization of Chinese Medicine will be accessible via livestream.The organiser will make appropriate arrangements to ensure the safety of those already at the venue and will closely monitor the weather conditions. The organiser will open the Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo two hours after the Black Rainstorm Warning Signal is cancelled.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月13日 - (亞太商訊 via SeaPRwire.com) - 億勝生物科技有限公司（「億勝生物」或「集團」，股票代碼：1061.HK）欣然宣布，集團針對重組抗VEGF眼內注射液EB12-20145P（HLX04-O）的上市註冊申請（「BLA」）最近已被中國國家藥品監督管理局（「NMPA」）藥品審評中心（「CDE」）受理。該產品由集團與上海復宏漢霖生物技術股份有限公司（「復宏漢霖」，股票代碼：2696.HK）合作開發，用於治療濕性年齡相關性黃斑變性（wet age-related macular degeneration, 「wet-AMD」）。此注射液EB12-20145P（HLX04-O）在中國患者中開展的III期臨床研究（「AURA-1」）已於今年4月成功達到主要研究終點。AURA-1為一項多中心、隨機、雙盲、陽性對照的非劣效III期臨床研究，旨在比較EB12-20145P（HLX04-O）與雷珠單抗玻璃體內注射（IVT）治療新診斷的wet-AMD患者的有效性和安全性。除其BLA已獲NMPA受理申請的AURA-1外，EB12-20145P（HLX04-O）的一項國際多中心III期臨床研究（AURA-2）也在歐洲多個國家、澳大利亞、美國和中國順利開展，AURA-2最後一名患者的最後一次訪視已在2025年1月完成。未來，億勝生物將不懈追求卓越，擁抱創新，持續推動對同類首創(First-in-class)與同類最優(Best-in-class)產品的創新研發，以滿足未來更多的臨牀及商業化需求。關於濕性年齡相關性黃斑變性年齡相關性黃斑變性（AMD）是造成老年人視力損害和不可逆失明的主要原因之一[1]，根據世界衞生組織報告，全球約有3000萬AMD患者，每年約有50萬人因為AMD而致盲[2]。AMD致盲患者中，以脈絡膜新生血管（CNV）為特徵的濕性年齡相關性黃斑變性（wet-AMD）比例高達90%。隨着老年人口比例的不斷上升，wet-AMD已經成為一個日益嚴重的社會醫學問題，存在着巨大的未滿足的臨床需求[3]。隨着眼底治療方法的突破與發展，抗VEGF藥物已成為wet-AMD的一線療法[4]，貝伐珠單抗玻璃體腔注射治療wet-AMD的有效性和安全性也已在多項臨床研究中得到驗證[5-11]。關於億勝生物（股票代碼﹕1061.hk）億勝生物是一間專注於研發、生產和銷售基因工程藥物b-bFGF的生物製藥企業，擁有包括貝復舒(R)、貝復濟(R)、貝復新(R)在內的六種基因工程藥物在中國上市銷售。此外，公司還擁有包含一系列不含防腐劑單劑量滴眼液和適麗順(R)卵磷脂絡合碘膠囊等的多元化產品組合，主要應用於眼科及皮膚科處方藥領域的創傷修復及疾病治療。這些產品在公司於中國的44個區域辦事處的支持下，在逾14,000家醫院進行營銷和銷售。依託自身在生長因子和抗體技術領域的研發平台，億勝生物在多個臨床階段擁有強大的項目管線，涵蓋廣泛的領域和適應症。参考文献[1] 欧阳灵艺, 邢怡桥. 抗VEGF药物在湿性年龄相关性黄斑变性中的应用进展[J]. 国际眼科杂志, 2020(1).[2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51.[3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2): e106-116.[4] Li X R, Liu J P. Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292.[5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi-centre randomized double masked study. BMJ. 2010 Jun 9;340:c2459.[6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908.[7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411.[8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9.[9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52.[11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5): e0153052. Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月13日 - (亞太商訊 via SeaPRwire.com) - 2025年8月8日，全球知名指數公司MSCI公佈了最新一輪指數審議結果，潼關黃金（00340.HK）成功獲納入MSCI全球小型股指數（MSCI Global Small Cap Indexes）成份股，相關調整將於2025年8月26日收市後正式生效。躋身頂級指數，擁抱全球資本洪流MSCI指數是全球最具影響力的金融指數體系之一，被廣泛視為全球機構投資者的重要參考基準。據統計，目前全球追蹤MSCI指數的資金規模已超過17萬億美元，其中被動型基金規模達到2萬億美元。然而，MSCI全球小型股指數專注於篩選全球市場中業績亮眼、成長潛力突出的中小市值企業。該指數成份股篩選嚴格，調整機制靈活，能夠緊密跟蹤市場動態，成為眾多國際大型投資機構的投資參考依據。本次MSCI季度指數調整將於8月26日收盤後正式生效。根據過往調整經驗來看，臨近調整生效時，相關的指數基金、ETF以及以MSCI指數為參考的主動管理基金都將進入集中調倉階段，新增成份股的成交量會在調整前後顯著放大，股價波動性可能上升。從機構觀點來看，高盛維持對北亞（中國、日本、韓國）和部分週期性股票的增持評級，預計MSCI亞太指數未來12個月以美元計價的價格回報率為9%。以2025年5月MSCI指數調整為例，新晉成份股複宏漢霖（02696.HK）在生效後的累計漲幅超60%，充分體現了市場對指數納入效應的積極回饋。業績爆發式增長，夯實價值根基潼關黃金獲得MSCI青睞絕非偶然，其堅實的業績高增長提供了最強支撐。根據公司7月31日發佈的盈喜公告，2025年上半年，公司擁有人應占溢利預計將錄得約3.3-3.6億港元，同比大幅增長259%-291%。高速增長主要得益於兩大核心驅動因素：礦產黃金產量與銷量的顯著提升，以及報告期內礦產黃金平均銷售價格的上行。量價齊升的優異表現，展現公司卓越的運營能力與行業景氣度回升帶來的紅利。值得一提的是，MSCI在篩選成份股時，不僅關注當前業績，更獨具慧眼地發掘那些當前價值可能被市場部分忽視、但未來具備巨大上升空間的潛力企業。潼關黃金亮眼的盈利能力結合其在行業內的戰略佈局，完美契合了MSCI這一"價值發現者"的選股邏輯，其納入實至名歸。提升國際能見度，開啟價值重估與進階之路潼關黃金獲納入MSCI全球小型股指數，標誌著公司正式進入全球主流投資機構的視野，戰略意義深遠。此次納入將顯著拓寬國際投資者基礎，提升公司在資本市場的知名度與流動性。被動資金的配置需求與主動投資者的關注度提升，有望推動估值中樞上移，實現市值躍升的重要正向催化力量。尤為關鍵的是，此里程碑事件為公司未來爭取納入更重要的基準指數（如恒生指數系列）以及港股通資格奠定基礎，為潼關黃金描繪出進階更高層級資本市場的清晰路徑。未來，隨著潼關黃金在國際資本舞臺能見度的持續提升以及向恒生指數成份股等關鍵領域邁進的步伐，潼關黃金的資本市場故事，正翻開更具想像力的新篇章。黃金賽道上的這位"新貴"，其光芒正愈發璀璨。 Copyright 2025 亞太商訊 via SeaPRwire.com.

Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 13, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the resumption of work on the Environmental and Social Impact Assessment ("ESIA") for its 100%-owned Lac Knife flake graphite project located near Fermont, in the province's prolific iron ore mining district.The Company has formally re-engaged IOS Geosciences Inc. ("IOS"), a leading Québec-based geological consulting firm and former general contractor on the ESIA, to complete a total of sixteen (16) technical reports required for submission to Québec's environmental and natural resource authorities. These reports represent a major step in advancing the Lac Knife project toward permitting and the goal of mine construction.The ESIA program, initially launched in 2020, involves multidisciplinary technical evaluations and environmental baseline work conducted across 2020 and 2021. Finalization was delayed due to funding constraints but is now back on track. Report completion is estimated by early 2026, with submissions planned shortly thereafter to the Québec Ministry of Sustainable Development, Environment, and the Fight Against Climate Change ("MDDELCC"), as well as the Ministry of Natural Resources and Forests ("MRNF").The sixteen (16) technical reports in progress cover critical permitting areas, including:Condemnation and pit wall drillingAcid-generating potential analysisGeotechnical drilling and soil mechanicsSoil geochemistry and chemistry baselineLake-bottom geochemical and surface water quality surveysGroundwater habitat assessment and follow-upCaribou habitat assessment and follow-upGeometallurgical and graphite flake characterizationThese comprehensive studies are essential for satisfying Québec's rigorous environmental and social licensing requirements and underscore Focus Graphite's commitment to environmental stewardship and Indigenous engagement through project development.In parallel, Focus has also authorized IOS proceed with geochemical analysis of over 1,000 split and pulverized drill core samples collected from its 2022 exploration drilling program at the Lac Tétépisca ("Tétépisca") graphite project. The samples, targeting the Southwest MOGC and West Limb geophysical (MAG-EM) conductors, will undergo carbon and sulfur determinations at certified laboratories.Upon receipt of assays, IOS will finalize and submit the corresponding technical reports covering 14,900.5 metres of core drilling from 74 holes to the MRNF. An updated Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") and National Instrument ("NI") 43-101 compliant Mineral Resource Estimate ("MRE") for the Manicouagan-Ouest Graphitic Corridor ("MOGC") graphite deposit is anticipated in Fall 2025, which will further define Tétépisca's development potential alongside Lac Knife."Resuming the ESIA is a pivotal milestone that moves us closer to full permitting and our goal of mine development at Lac Knife," said Dean Hanisch, CEO of Focus Graphite. "With most fieldwork and laboratory studies already complete, we're in a strong position to finalize this critical stage efficiently. At the same time, initiating assay work at Tétépisca to support an upgraded mineral resource estimate reflects our commitment to building value across our entire Québec asset base."The Company also announced the grant of incentive stock options as compensation to its directors, officers, employees, and consultants. Options to purchase up to 4,215,000 Common Shares of the Company have been granted at an exercise price of $0.14 per share. The options expire on 13 August, 2030. Additionally, the Company has granted 1,350,000 restricted stock units ("RSUs") to officers, directors, and consultants of the Company under the terms of the Company's restricted share unit and equity incentive plan (the "RSU and EIP Plan"). Each RSU entitles the holder to acquire one common share of the Company after the vesting period in accordance with the Plan.Qualified PersonsThe technical content disclosed in this news release was reviewed and approved by Réjean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the completion and submission of the sixteen technical reports required for the Lac Knife Environmental and Social Impact Assessment, the anticipated timeline for ESIA report submission and permitting, the initiation and results of geochemical analyses at the Lac Tétépisca project, the anticipated updated NI 43-101 Mineral Resource Estimate for the Tétépisca deposit, the Company's positioning as a near- and long-term secure supplier of specialty graphite materials, and the potential geopolitical significance of Canadian graphite supply.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262450 Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月13日 - (亞太商訊 via SeaPRwire.com) - 備受全球科技界矚目的世界人形機器人運動會將於8月14日在北京國家速滑館正式揭幕，這場持續至8月17日的科技盛宴，將成為展示全球人形機器人技術最高水平的重要窗口。作為全球首個以人形機器人為核心參賽主體的大型綜合性賽事，本屆運動會設置了極具看點的多元競賽項目。來自世界各地的超百支頂尖機器人戰隊，將在跑步、足球、街舞、武術、工廠搬運、酒店服務等項目中同場競技，全面展示人形機器人在不同領域的應用潛力。這背後不僅是技術的較量，更是對機器人適應複雜環境、完成精細任務能力的全方位檢驗，每一項比賽都凝聚着人工智慧、機械工程等多學科的技術突破。一、首程控股多維度深度參與在本屆運動會中，首程控股同時扮演資本推動者、場景驗證者及生態運營者的三重角色。依託管理的北京機器人產業發展投資基金及多支產業基金，首程已系統投資布局數十家高成長機器人企業，涵蓋從核心零部件到整機集成、從底層算法到場景應用的全產業鏈。此次亮相的被投企業包括：宇樹科技（Unitree Robotics）、銀河通用（Galbot）、星海圖（Galaxea-AI）、松延動力（Noetix Robotics）、加速進化（Booster Robotics）及自變量機器人（X Square Robot）等，分別在足球、田徑、格鬥、舞蹈、場景賽等核心項目中擔綱主力。二、首程機器人科技體驗店打造沉浸式產業櫥窗運動會期間，位於國家速滑館內的首程機器人科技體驗店同步開放，集中展示50餘家企業近200款產品，涵蓋智慧家居、教育、智能穿戴、娛樂休閒等多個場景。觀眾不僅可近距離體驗人形機器人、智能家電、AI娛樂設備等前沿產品，亦可現場購買，實現「發布-測試-銷售-服務」的消費閉環。該舉措與首程於2025年啟動的全球「機器人綜合體驗店」招募計劃一脈相承，並將為未來在融石廣場等地開設的長期體驗店積累場景與營運經驗。首程控股董事會主席趙天旸表示，機器人市場規模未來將超越汽車行業，中國必將誕生百億美元市值的機器人企業。通過運動會這一「產業櫥窗」，首程不僅展示被投企業的技術實力，更在真實環境中驗證其商業化潛力，加速技術從「實驗室走向市場」的進程。三、租賃公司保障賽事落地為保障賽事前期訓練與正式比賽，北京機器人租賃公司集中交付了100台賽事指定設備，包括82台Booster Robotics足球賽本體、10台Noetix Robotics田徑機器人及8台Galaxea-AI場景賽機器人。全部設備已進駐國家速滑館，重點服務於足球、田徑及場景賽的訓練需求，並由租賃公司與廠商技術團隊聯合駐場提供全流程技術支持，實現「即交付、即服務」的產業響應。觀賽互動福利為感謝市場長期支持，首程控股將抽籤選出88位幸運觀眾親臨現場，見證這場全球頂尖科技的競技舞台。報名截止時間：2025年8月14日（北京時間）上午9:00抽籤時間：2025年8月14日下午3點前公佈，受邀者將收到電郵或短信通知參與方式：1.通過鏈接填寫報名信息：https://www.wjx.cn/vm/mfW64yI.aspx#2.關注「首程控股」官方微信公眾號，後台留言「機器人運動會」，按彈出鏈接填寫報名信息。 Copyright 2025 亞太商訊 via SeaPRwire.com.

康基醫療控股有限公司與Knight Bidco Limited今日聯合宣佈，擬通過協議安排（"建議交易"）對公司進行私有化。康基醫療控股有限公司私有化要約：每股9.25港元的註銷價較股份於截至未受干擾日期（即2025年6月30日）之收盤價溢價約21.7%，較股份於截至未受干擾日期（包括該日）止360個交易日在聯交所所報的平均收盤價溢價約47.3%，且超過了2022年以來於聯交所錄得之最高收盤價。本次私有化擬以協議安排實施，要約人及其一致行動人士合共持有公司74.75%之股份；已獲得一家機構股東作出的不可撤銷承諾，將投票支持該私有化方案。該方案為股東提供明確機會，使其能夠於康基醫療控股有限公司之股份持續面臨交易價格壓力及流動性受限之際，變現其於公司之權益。香港，2025年8月13日 - (亞太商訊 via SeaPRwire.com) - 2025年8月12日，康基醫療控股有限公司（「康基醫療」或「公司」，股份代號：9997.HK）與KNIGHT BIDCO LIMITED「要約人」今日聯合宣佈，雙方擬以協議安排的方式對公司進行私有化，以期公司能夠專注於長期戰略決策，包括研發長期投入及運營升級。待該方案完成後，公司將成為要約人的全資附屬公司，而公司股份於聯交所的上市地位將被撤銷。要約人由以下成員組成的財團全資持有：鍾先生與申屠女士（創始人）、TPG實體、NewQuest V基金及Al-Rayyan Holding。交易理據鑒於股票的交易價格持續承壓且流動性長期不足，公司從股票市場籌集資金的能力受到嚴重限制。除此之外，本公司為維持上市地位須承擔行政、合規及其他與上市相關之成本及開支，故維持上市地位之裨益有限。由於國內市場競爭加劇及持續之監管不確定性，為實現可持續增長，公司之長期策略需進行重大投資，此舉可能對短期財務表現造成壓力。預計需將額外資源分配至以下領域：銷售與市場推廣、研發及商業化投資，以及中國境外之市場擴張。鑒於維持上市地位之裨益有限，且涉及相關上市成本，康基醫療繼續維持上市地位之必要性已顯著降低。此外，該方案之實施將緩解公司短期財務表現所受壓力，從而更專注於戰略目標之推進。公司預期需要配置更多資源，以保障其未來可持續發展。此外，該方案為少數股東提供具吸引力之機會，使其能在市場波動、行業及宏觀不確定性，以及股份流動性有限之情況下，實現可觀回報。KNIGHT BIDCO LIMITED提出的私有化方案為康基醫療及其股東提供了及時有效的解決方案，提議將康基醫療私有化的方案將：(a) 降低康基醫療的行政、合規及其他上市相關成本；(b) 緩解康基醫療面臨的短期業績指標壓力，使康基醫療能夠專注於長遠戰略決策（例如可能導致短期虧損的長期研發投入及運營升級）；以及(c) 為現有股東提供明確保障，使其能以顯著高於未受干擾股價之溢價，實現於康基醫療之權益變現。綜上所述，要約方認為私有化交易能為全體股東提供即時且最具吸引力價值的戰略選擇，同時可規避不確定市場環境帶來的風險。交易方案概述本次私有化方案設定的股份註銷價格為每股9.25港元，按股權價值計算對公司估值約為14億美元。[1]要約方已明確表示，註銷價格為最終定價且後續不會上調。該註銷價格體現以下考量：較股份於未受干擾日期（即2025年6月30日）在聯交所所報收盤價溢價約21.7%。較股份於截至未受干擾日期（包括該日）止360個交易日在聯交所所報的平均收盤價溢價約47.3%。以及截至未受干擾日期（包括該日）止於聯交所所報之股份價格的過去52週最低收盤價（5.01港幣）溢價約84.6%。此外，在較長的過往期間內，註銷價格超過了股份自2022年以來的最高收盤價（8.66港幣）。本次註銷價格的確定已綜合考量下列因素（包括但不限於），股份於聯交所的近期及歷史交易價格，公司公開披露的財務資訊，及參照近年來香港市場類似私有化交易案例。該方案的實施受限於所有先決條件於2026年1月31日（先決條件最後截止日期）或之前達成，並在2026年4月30日（最後截止日期）之前滿足條件。公司將委任獨立財務顧問（"IFA"）向為方案目的而設立的獨立董事委員會（"獨立董事委員會"）提供意見，以便就方案向股東作出推薦建議。方案的詳情，包括獨立董事委員會的最終推薦意見及獨立財務顧問的意見函，將載入計劃文件，並預期在切實可行的情況下儘快寄發給股東。協議安排會議協議安排會議的具體細節將載於計劃文件，該文件預計將於適當時候寄發予股東。本次交易尚需滿足《聯合》公告所列的多項先決條件及條件，包括但不限於監管批准、股東批准及其他法定合規要求。不可撤銷承諾本公司已獲得一名機構股東作出的不可撤銷承諾，將就該項提案投贊成票。詳情請參閱《聯合公告》。康基醫療已於2025年7月18日上午9時正起於聯交所暫停買賣，以待刊發本公告。公司已向聯交所申請股份自2025年8月13日上午9點起恢復買賣。摩根大通擔任要約方獨家財務顧問關於康基醫療控股有限公司康基醫療控股有限公司創立於2004年，總部位於中國浙江省杭州市，於2020年6月在香港聯合交易所主板上市，股票代碼9997.HK。公司專注于設計、開發、生產和銷售微創外科手術器械及配套耗材(「MISIA」)，秉持著「為醫生提供優質產品和服務，致力於人類健康事業」為使命，通過豐富的產品組合為婦產科、普外科、泌尿外科和胸外科等臨床科室的微創外科手術提供一站式解決方案，並致力於發展為一個立足中國，輻射全球的國際化微創外科手術器械及配套耗材平台。關於Knight Bidco Limited要約人、MidCo 及TopCo均為於開曼群島新註冊成立的有限公司及僅為實施該建議而成立的投資控股公司。於本公告日期，要約人由MidCo全資擁有，而MidCo由TopCo全資擁有。於本公告日期，TopCo由財團成員持有，其中Fortune Spring ZM、Fortune Spring YG、TPG Asia VII、Keyhole、Knight Success、NewQuest V及Al-Rayyan Holding分別持有約25.53%、約14.47%、約24.38%、約5.01%、約5.69%、約4.56%及約20.36%。截至本公告發布之日，除聯合公告中「公司的股權架構」一節所披露外，TPG Asia VII、Keyhole、Knight Success、NewQuest V及Al-Rayyan Holding 均非股東。康基醫療現由鍾鳴先生及其配偶申屠女士共同控制，二人合計持有康基醫療52.98%股份。待私有化完成後，鍾氏夫婦將通過"Fortune Spring ZM"與"Fortune Spring YG"繼續持有要約方最終控股公司（TopCo）40.00%股權，並保持第一大股東地位。更多細節詳見《聯合公告》。各創始人實體均為英屬維爾京群島註冊成立的商業公司。Knight Success為一家於新加坡新註冊成立的有限公司及且為一家投資控股公司。Keyhole為一家於開曼群島註冊成立之獲豁免有限公司及投資控股公司。TPG Asia VII為一家於新加坡註冊成立的有限公司。Knight Success 及Keyhole均由TPG Asia VII全資擁有或控制，而後者由TPG Asia GenPar VII Advisors, Inc.控制，並最終由納斯達克上市的特拉華州公司TPG Inc. 控制。TPG是一家全球領先的另類資產管理公司，成立於1992 年，截至2025年6月30日年管理的資產超過2,690億美元。多年來，TPG一直致力於投資變革、增長與創新，旨在為投資者構建多元化的產品與策略，同時藉由貫徹紀律及卓越的營運管理，提升投資策略與投資組合的整體表現。NewQuest V為一家於新加坡註冊成立的有限公司及投資控股公司。NewQuest V由NewQuest Asia Fund V, L.P. 全資擁有，而後者由NewQuest Asia Fund V GP Ltd.控制，並最終由納斯達克上市的特拉華州公司TPG Inc.控制。NewQuest成立於2011年，是亞洲領先的二級私募股權平台之一，擁有亞洲最有經驗的二級團隊，分佈於五個辦事處。自成立以來，NewQuest 一直專注於與普通合夥人合作，創建定制的解決方案，以滿足私募資產持有人及其利益相關者的流動性和其他戰略需求。從2018年建立的戰略合作夥伴關係開始，NewQuest 於2022 年1月成為TPG的全資附屬公司。Al-Rayyan Holding為一家根據卡塔爾金融中心管理局的規定於2012年在卡塔爾成立的有限責任公司，且為卡塔爾主權財富基金卡塔爾投資局全資擁有的間接附屬公司。成立於2005年的卡塔爾投資局旨在投資和管理國家儲備基金。卡塔爾投資局為全球最大、最活躍的主權財富基金之一。卡塔爾投資局投資於廣泛的資產類別及地區，並與世界各地的領先機構合作，建立具有長期前景的全球化及多元化投資組合。於本公告日期，Al-Rayyan Holding 及其一致行方（與Al-Rayyan Holding 單獨或被視為與該財團一致行事的各方除外）均不持有任何股份。如有垂詢，敬請聯繫：康基醫療控股有限公司要約人傳媒聯絡：皓天財經集團有限公司Angie Li & Jason Lai電話：(852) 6150 8598 / (852) 9798 0715電郵：po@wsfg.hk傳媒聯絡: 博然思維Kay Lau+852 6021 7009Tong Li+86 134 8872 6729電郵：TeamKnight@brunswickgroup.com[1] 以每股9.25港币的注销价格、1,207,994,000股流通股，以及7.85的美元兑港币汇率计算免責聲明：本新聞稿中使用的所有未另行定義的大寫術語，其含義均以2025 年 8 月 12日 發佈的《聯合公告》中的釋義為准。本新聞稿須與《聯合公告》全文一併閱讀，公告副本可在以下鏈接查閱。https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201339_c.pdf Copyright 2025 亞太商訊 via SeaPRwire.com.

SINGAPORE, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Artificial intelligence has many uses in daily life. From personalized shopping suggestions to voice assistants and real-time fraud detection, AI is working behind the scenes to make experiences smoother and more seamless. Behind every smart AI feature is a process that involves two distinct stages: AI training and AI inference. While they're both essential to building intelligent systems, they serve very different purposes and have unique requirements. Let's break down the differences between training and inference.What is AI training?AI training is the process of feeding an AI model large volumes of data, so it learns to recognize patterns and generate the required output.Training generally requires large volumes of labeled or unlabeled data, each of which may facilitate different forms of training.Labeled data: Some projects require a model to make decisions or generate output based on established patterns or correlations. Here, it makes sense to train the model on labeled data using supervised learning techniques.Unlabeled data: Training models on unlabeled data lets them detect new patterns and build an understanding of the relationships between inputs and outputs. This is called unsupervised learning.Think of AI training like teaching a student using flashcards, quizzes, and feedback. During training, the model constantly adjusts internal parameters (often millions or billions of them) to minimize errors and improve accuracy. This phase is computationally intensive and requires specialized hardware like GPUs or TPUs to process large datasets efficiently.For example, training an AI model to recognize objects in images might involve showing it millions of labeled photos of cats, cars, and coffee mugs until it can correctly identify these objects on its own.What is AI inference?Once a model has been trained, it's ready to perform tasks. AI inference is the process of using a trained model to make predictions or decisions on new, unseen data.Inference is typically faster and more lightweight than training. It's used in real-time applications like chatbots, recommendation engines, voice recognition, and edge devices like smartphones or smart cameras. Inference is the test of training. If the output or predictions from your model are inaccurate, you may need to go back to testing.Going back to the earlier example, inference is what happens when you upload a photo to your phone and the AI instantly recognizes your pet as a "cat." The model has been trained to recognize cat images; it just applies what it already knows.Where AI training and inference differThough both stages are part of the same AI lifecycle, they differ significantly in purpose, speed, and system requirements. Here's a closer look at the key differences:ObjectiveTraining aims to teach the AI model by exposing it to data and helping it learn relationships, rules, and patterns.Inference uses the trained model to generate output (such as predictions, classifications, or decisions) based on new data.Time takenTraining can take hours, days, or even weeks, depending on the size of the model and the complexity of the data. It's a resource-heavy, iterative process.Inference happens much faster, often in real time or near real time.Infrastructure needsTraining requires high-performance computing resources such as powerful GPUs or TPUs, and large memory bandwidth. Most training happens in cloud environments or specialized data centers.Inference can often run on lower-powered devices, including edge hardware like mobile phones or IoT devices. Dedicated inference servers or GPU instances may still be needed in some cases.AI training and inference work hand in hand, but they have different goals, requirements, and challenges. Training is about teaching the model, and inference is about putting it to work. Organizations planning AI projects must consider both phases when budgeting, selecting hardware, and choosing infrastructure.CONTACT:Sonakshi MurzeManagersonakshi.murze@iquanti.comSOURCE: OneMain Financial Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - The highly anticipated World Humanoid Robot Games will officially open on 14 August at the Beijing National Speed Skating Oval and run through 17 August. This four-day technological extravaganza will serve as a premier showcase for the world’s most advanced humanoid robot technologies.As the world’s first large-scale comprehensive competition featuring humanoid robots as the main participants, the Games will include diverse and highly anticipated events such as running, football, street dance, martial arts, factory logistics, and hotel services. Over 100 top-tier robotics teams from around the globe will compete, fully demonstrating the application potential of humanoid robots across multiple domains. Beyond a contest of technology, the Games will be a comprehensive test of robots’ adaptability to complex environments and their ability to perform precision tasks, representing breakthroughs across AI, mechanical engineering, and other disciplines.1. Multi-Dimensional Involvement of Shoucheng HoldingsIn this year’s Games, Shoucheng Holdings acts as a capital enabler, scenario validator, and ecosystem operator. Through the management of the Beijing Robotics Industry Development Investment Fund and other industrial funds, Shoucheng has systematically invested in dozens of high-growth robotics companies, covering the entire value chain from core components to system integration, from fundamental algorithms to scenario applications. Its portfolio companies participating in the Games include Unitree Robotics, Galbot, Galaxea-AI, Noetix Robotics, Booster Robotics, and X Square Robot, each taking a leading role in core events such as football, track-and-field, combat, dance, and scenario competitions.2. Shoucheng Robotics Technology Experience Store – An Immersive Industry ShowcaseDuring the Games, the Shoucheng Robotics Technology Experience Store located inside the National Speed Skating Oval will be open to the public, displaying nearly 200 products from over 50 companies. These exhibits span smart home, education, wearable tech, and entertainment sectors. Visitors can experience cutting-edge products such as humanoid robots, smart appliances, and AI entertainment devices up close, and make on-site purchases – completing a “launch–test–sales–service” consumer loop. This initiative aligns with Shoucheng’s global “Robotics Comprehensive Experience Store” recruitment program launched in 2025, and will provide valuable operational insights for permanent experience stores planned at locations such as Rongshi Plaza.Chairman Zhao Tianyang stated that the robotics market will eventually surpass the automotive industry in scale, and that China will see the emergence of robotics companies valued at tens of billions of US dollars. Through the Games as an “industry showcase”, Shoucheng is not only presenting the technological strengths of its portfolio companies, but also validating their commercial potential in real-world environments – accelerating the journey from “lab to market.”3. Leasing Company Ensures Event DeliveryTo support training and official competitions, Beijing Robotics Leasing Company has delivered 100 designated competition robots, including 82 Booster Robotics football units, 10 Noetix Robotics track-and-field robots, and 8 Galaxea-AI robots for scenario events. All equipment has been deployed at the National Speed Skating Oval, serving training needs for football, track-and-field, and scenario competitions. The leasing company, together with manufacturer technical teams, has established an on-site service team to provide end-to-end technical support, achieving “immediate delivery, immediate service” responsiveness.Spectator EngagementTo thank its long-term supporters, Shoucheng Holdings will draw 88 lucky spectators to attend the Games in person and witness this world-class robotics competition.- Registration deadline: 14 August 2025, 9:00 a.m. (Beijing time)- Draw announcement: Before 3:00 p.m. on 14 August 2025 (Beijing time), with invitations sent via email or SMSParticipation methods:1.Fill out the registration form via: https://www.wjx.cn/vm/mfW64yI.aspx#2.Follow the official WeChat account 'Shoucheng Holdings', leave the message 'Robot Games', and complete the form via the link provided. Copyright 2025 ACN Newswire via SeaPRwire.com.

Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”).Proposed privatisation of Kangji Medical Holdings LimitedThe Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the ProposalThe Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidityHONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Aug 12 2025, Kangji Medical Holdings Limited (“Kangji Medical” or the “Company”, Stock Code: 9997.HK) and Knight Bidco Limited (the “Offeror”) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding. Rationale for the ProposalDue to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company's long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.Overview of the ProposalThe proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]The Offeror has indicated the Cancellation Price is final and will not be increased further.The Cancellation Price reflects:A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.Scheme MeetingDetails of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.Irrevocable UndertakingAn Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.J.P. Morgan acted as the exclusive financial advisor to the Offeror.Kangji Medical Holdings LimitedKangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.About Knight Bidco LimitedEach of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Joint Announcement.Each of the Founder Entities is a business company incorporated in the British Virgin Islands.Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.For enquiries, please contact:Kangji Medical Holdings LimitedOfferorMedia contact: Wonderful Sky Financial Group LimitedAngie Li & Jason LaiTel: +852 6150 8598 / +852 9798 0715Email: po@wsfg.hkMedia contact: Brunswick GroupKatelin Stevenson & Tong Li+852 9875 3351 / +86 134 8872 6729TeamKnight@brunswickgroup.com[1] Based on HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月12日 - (亞太商訊 via SeaPRwire.com) - 五礦資源有限公司（「MMG」；股份代號：1208）今日發佈二零二五年中期業績，公司除稅後淨利潤達566.3百萬美元，較二零二四年上半年的除稅後淨利潤79.5百萬美元增長逾600%。這一強勁利潤提升主要得益於旗下三座銅礦的銅產量均有所增長，銅、金、銀、鋅的市場價格上揚，以及Las Bambas因銅產量提升而實現單位成本下降。MMG行政總裁趙晶表示：「今年上半年，MMG的業務實現了卓越的經營和財務表現。此成果充分展現出公司資產組合的優勢、團隊的卓越能力以及對戰略規劃的堅定執行力。」值得關注的是，二零二五年上半年，MMG的安全績效有所改善，每百萬工作小時可記錄總工傷事故頻率（TRIF）為1.81，低於二零二四年全年的2.06。二零二五年上半年具有能量交換的重大事件頻率（SEEEF）為每百萬工作小時0.78，與二零二四年持平。運營方面，公司旗下三座銅礦山的銅銷量與產量均顯著提升，其中Las Bambas表現強勁，Khoemacau和Kinsevere亦處於爬坡階段。澳大利亞兩座礦山雖面臨天氣影響、設備可靠性以及採礦順序導致的品位下降等挑戰，鋅產量仍保持穩定。要點：上半年的EBITDA及EBIT均創下歷史新高，其中EBITDA達1,539.9百萬美元，較二零二四年上半年增長98%，而EBIT總計1,058.8百萬美元，較去年同期增長240%。除稅後淨利潤達566.3百萬美元，包括本公司權益持有人應佔利潤340.0百萬美元。經營活動現金流淨額較二零二四年上半年增長130%，總額達1,185.0百萬美元。這主要受銅銷售量增加及商品價格上漲推動。資產負債持續改善，自Las Bambas收購以來，債務淨額及槓桿率均創下歷史新低。其中，債務淨額自二零二四年底以來減少903.3百萬美元，主要得益於強勁的運營現金流及提前償還Khoemacau合營公司集團500百萬美元的貸款。二零二五年上半年，槓桿率從41%下降至33%。二零二五年上半年，應付銅銷售總量達237,651噸，創二零一八年以来歷史新高。Las Bambas二零二五年上半年銅精礦含銅的產量達210,637噸，較二零二四年同期增長67%。EBITDA創下歷史新高，達1,310.5百萬美元，較二零二四年上半年增長122%。趙晶補充道：「MMG的資產負債表達至十年來最穩健水平--受惠於盈利提升和現金流創造帶動的債務削減。我們躋身全球十大銅生產商的目標觸手可及，透過卓越的運營表現、審慎的資本分配，以及對負責任採礦的持續承諾，我們已為實現這一目標奠定良好基礎。」二零二五年的生產指引維持不變，銅總產量最高可達522,000噸，鋅產量最高可達240,000噸。如果運營環境穩定且無外部干擾，Las Bambas今年有望實現高達400,000噸的銅產量。MMG正致力達成成本目標，Las Bambas和Rosebery已下調C1成本區間，以反映副產品收益改善及強勁的市場條件。本公司正努力完成近期對巴西鎳業的收購，並對公司的長期資產組合及增長前景充滿信心。MMG將持續推動運營所在社區的發展，促進當地經濟與就業，並為全球可持續未來供應所需的關鍵礦物。點擊查看完整的中期業績報告，觀看行政總裁致辭視頻以及下載公司圖片。關於MMGMMG成立於二零零九年，其願景是為低碳未來打造國際領先的礦業公司。公司總部位於澳大利亞墨爾本和中國北京，並在香港聯合交易所上市（聯交所：1208）。MMG的资产組合涵蓋銅、鋅和鈷的生產，並即將拓展至鎳領域。這些金屬資源對全球脫碳和電氣化目標的實現至關重要。目前，公司的運營業務分佈澳大利亞、博茨瓦納、剛果民主共和國及拉丁美洲。更多信息請點擊此處。 Copyright 2025 亞太商訊 via SeaPRwire.com.

俄亥俄州西湖, 2025年8月12日 - (亞太商訊 via SeaPRwire.com) - 全球領先的高性能聚合物解決方案配方、研發和製造企業GEON®高性能解決方案公司今日宣布，其位於美國、加拿大、墨西哥和中國的分支機構已獲得Great Place To Work®（GPTW，「最佳職場」）認證。自2021年與GPTW合作以來，GEON一直秉持著文化與可持續發展的願景，力爭每年都獲得這一殊榮。通過 GPTW 認證GEON獲美國、加拿大、墨西哥和中國「最佳職場」認證。GPTW要求員工對自身體驗、職場文化以及領導行為進行量化評估和基準比較，這些因素已被證明能夠帶來市場領先的營收、員工留任率的提升以及創新能力的增強。「我們非常高興能在公司運營的四個國家連續兩年獲得『最佳職場』認可。『最佳職場』的評選是與全球頂尖僱主進行比較的，這證明了我們在追求卓越企業文化的道路上正走在正確的方向上。」GEON首席執行官特蕾西‧加里森（Tracy Garrison）表示，「我們相信，市場上的領導者也必須是職場上的領導者。為此，我們在全球各地的運營中都致力於營造積極的工作文化，同時努力在仍需提升的領域不斷進步。」GEON獲得了79%的員工敬業度評分，比典型公司高出20%以上。在美國、加拿大和中國，GEON的評分較去年有所提升，在墨西哥則保持穩定。美國的調查涵蓋了GEON的所有員工，包括 GEON於2025年1月收購的Foster, LLC 的員工。根據 Great Place To Work research 的研究，在獲得「最佳職場」認證的企業中，求職者找到優秀上司的可能性高出4.5倍。此外，在通過認證的企業工作，員工期待上班的可能性高出93%，並且獲得公平薪酬和公平晉升機會的可能性是普通企業的兩倍。「正如數據所示，獲得 GPTW 認證不僅反映了我們的企業文化，還直接影響了我們留住那些每天都期待來上班的優秀員工的能力。」GEON 首席人力資源官傑羅姆‧貝格里（Jerome Beguerie）表示，「這對我們的客戶以及他們與我們合作的體驗都有直接影響。」關於 GEON 高性能解決方案GEON® 高性能解決方案是聚合物混配解決方案領域的領先創新者，服務於包括建築與基礎設施、消費品、工業、交通運輸以及電力與通訊等在內的廣泛市場。通過收購 Foster, LLC，GEON 進一步增強了在高速增長的醫療保健和醫療器械行業的參與度，並在高度適應性的乙烯基、聚烯烴和工程樹脂技術組合基礎上，拓展了全方位合同製造業務。GEON 在全球擁有約 1,200 名員工和 15 家世界一流的製造工廠，總部位於俄亥俄州西湖市。了解更多資訊，請訪問 http://www.geon.com 。GEON 是 SK Capital Partners 投資組合中的一家公司。關於 SK CapitalSK Capital 是一家具有變革力的私募投資公司，專注於特種材料、配料以及生命科學領域。公司致力於打造具有韌性、可持續性和增長潛力的企業，從而創造可觀的長期價值。SK Capital 力求利用其在行業、營運和投資方面的經驗，尋找機會將企業轉型為具有更高績效、更優戰略定位、更強增長與盈利能力且營運風險更低的組織。截至 2024 年 12 月 31 日，SK Capital 管理的資產總額約為 100 億美元。更多資訊請訪問 http://www.skcapitalpartners.com 。聯絡資訊Renita AndersonVice President, Marketing & Business Developmentrenita.anderson@geon.com678-772-8953來源: GEON Performance Solutions Copyright 2025 亞太商訊 via SeaPRwire.com.

伊利諾州羅密維爾, 2025年8月13日 - (亞太商訊 via SeaPRwire.com) - 作為高性能材料分銷領域的領導者，Formerra 已與 Syensqo 簽署協議，負責在北美地區分銷其 Solef® 聚偏二氟乙烯（PVDF）材料。該協議擴大了這種關鍵材料的供應範圍，該材料以兼具耐化學性與柔韌性而聞名。Solef® PVDF 加入了 Formerra 日益壯大的高性能材料產品組合，旨在推動產品開發與創新。「透過這項新協議，Formerra 將能夠為多個市場的客戶提供所需材料，以滿足嚴苛的應用需求。」Formerra 業務開發經理 Bob Long 表示：「此外，這也進一步強化了我們的承諾，即為在複雜的性能與法規挑戰中前行的客戶，提供無與倫比的供應渠道、應用支援以及先進材料。」PVDF 因其優異的耐化學性與耐熱性，被定位於性能金字塔的頂端附近。其固有的柔韌性，更進一步提升了其在化學加工、醫療保健及汽車等行業嚴苛應用中的適用性。其主要特性*包括：耐熱性：可在高達 150 °C（302 °F）的環境中持續使用，於室溫下可承受高達 139 bar（2,017 psi）的爆破壓力化學純度：具超純水耐受性，符合半導體產業 SEMI F-57 規範強度與柔韌性的平衡：抗拉屈服強度可達 55 MPa（8,000 psi），斷裂伸長率可達 100%「我們選擇 Formerra 作為 Solef® PVDF 在北美的經銷合作夥伴，是基於他們在技術與商業領域的廣泛觸及能力。」Syensqo 特用高分子公司美洲區銷售總監（通路合作夥伴、經銷與數位銷售）Rose Catherin 表示：「他們對卓越的承諾，以及在關鍵市場的長期耕耘，使其成為擴大 Solef® PVDF 供應與應用的理想夥伴。」*以 TDS 測量標題：Formerra 成為 Syensqo Solef® PVDF 的北美區經銷商重點資訊：Formerra 是 Syensqo Solef® PVDF 在北美的授權經銷商。該協議涵蓋對多元產業高性能應用的支援。PVDF 具備優異的耐化學性、熱穩定性與柔韌性。Formerra 提供技術指導與供應鏈專業知識，協助材料選擇與應用開發。關於 FormerraFormerra 是領先的工程材料分銷商，將全球頂級聚合物與特種材料製造商與醫療保健、消費品、工業與移動出行等市場的數千家 OEM 與品牌商緊密連結。憑藉技術與商業專業能力，Formerra 提供獨特的產品組合深度、強大的供應鏈實力、深厚的產業知識、卓越的服務、領先的電子商務能力以及創新精神。經驗豐富的 Formerra 團隊協助各行業客戶以全新且更優的方式設計、選擇、加工及開發產品，從而提升性能、生產力、可靠性與永續性。欲了解更多資訊，請造訪 www.formerra.com。媒體聯絡Jackie MorrisFormerra 行銷傳播經理jackie.morris@formerra.com來源: Formerra Copyright 2025 亞太商訊 via SeaPRwire.com.